All News

Fever,temp,man,HA,thermometer

Rheumatic Causes for Fever of Unknown Origin

d Jack Cush, MD

Fever of unknown origin (FUO) represents a diagnostic challenge to many physicians and while cancer and infectious causes need to be excluded, rheumatic disorders are amongst the most common causes of FUO.

Read Article
blood, level, numbers, data, calculation

Best Labs for Still’s Disease

d Jack Cush, MD

There is no “test” (blood or other) that is solely diagnostic of Still’s disease, but labs can help make a diagnosis or manage disease, and affirm the safety of drugs in use. ​​​​​​​ 

Read Article
Best of

U.S. News & World Report’s 2022–23 Rheumatology Rankings

d Jack Cush, MD

The Johns Hopkins Hospital has repeated its top rank among US Rheumatology centers - ranking #1 for the 18th year in a row, according to U.S. News & World Report’s 2022–23 Best Hospitals list released yesterday.

Read Article
figure-1691868_640.jpg

TREAT EARLIER Study - Is MTX Intevention in Pre-Clinical RA Warranted?

d Jack Cush, MD

Management of arthralgias before a certified rheumatoid arthritis (RA) diagnosis is challenging - should one use DMARD therapy before clinically evident synovitis in a preemptive effort to avoid or forestall the diagnosis or damage of RA?

Read Article
IPF.JPG

Nintedinib’s Durable Efficacy in Systemic Sclerosis

d MedPage Today

Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said.

Read Article
mitochondrial,DNA

Mitochondria as Master Regulators of Inflammation

d Jack Cush, MD

Mitochondrial constituents and metabolic products may give rise to immune activation; this is especially true for mitochondrial DNA, which can function as damage-associated molecular patterns (DAMPs) leading to inflammasome activation.

Read Article
Single center, retrospective chart study shows that in 168 PsA patients, 26% were assessed within 6wks of referral. Median wait time = 78.5 d. The most common cause of delay was the lack of available spots in the PsA clinic. https://t.co/FDfFgxHhLD https://t.co/CYoT1PBp8l

Links:

Dr. John Cush RheumNow ( View Tweet)
No Risk of RA w/ coffee consumption -- Swedish EIRA study, included 2184 early RA pts. High Coffee (>6 cups/day) was assoc w/ increased RA risk (OR 1.50;1.20–1.88) that was lost after adjusting for smoking (OR 1.14;0.89–1.45). https://t.co/3SIeHD4fII https://t.co/NqkjmuzSaV

Links:

Dr. John Cush RheumNow ( View Tweet)
Nintedinib’s Durable Efficacy in Systemic Sclerosis Patients with interstitial lung disease (ILD) related to systemic sclerosis continued to see less progression when treated with nintedanib (Ofev) in the pivotal 100-week SENSCIS trial, researchers said. https://t.co/7rUuB6RRow https://t.co/MqBjOj1myW

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 13 trials of corticosteroids (CS) in hand #OA shows no significant effect of intra-articular CS for CMC1 OA (pain or function); but medium effect of oral CS on pain & stiffness & functional improvement at 4-6 weeks. https://t.co/u30bPuQOOr https://t.co/4Z1ZpiOcvX

Links:

Dr. John Cush RheumNow ( View Tweet)
EMA in Europe has approved Rinvoq (upadacitinib 45 mg and 15 mg and 30 mg) for the treatment of adult patients with moderately to severely active ulcerative colitis who are DMARD-IR or biologic-IR. Based on 3 phase III trials. https://t.co/BjvUm0wPNk https://t.co/IVisAgD1wZ

Links:

Dr. John Cush RheumNow ( View Tweet)
BSRBR mandates LFTs q3 mos if on MTX. 1011 RA pts during the pandemic had median of 5 blood tests & median interval of 57 days. 61% pts had 1 prolonged interval (99-150d) & 24% had multiple. Cytopenia & ^LFTs were not increased by interval length https://t.co/VqY4qIMvOS https://t.co/HcTcmFBuvq

Links:

Dr. John Cush RheumNow ( View Tweet)
210 consecutive #RA pts starting #MTX looked at effect of autoantibodies on drug response. DAS28-CRP low dz activity at 6 mos was significantly lower with SSA+ (56% v 76%, P=0.03) - which was more significant than CCP+ or RF+ https://t.co/DoEtldBXi4 Figures https://t.co/yIECjLiEwl

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders. https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz

Links:

Dr. John Cush RheumNow ( View Tweet)
Every moderately to severely immunocompromised person should know about Evusheld, a preventive Rx. It's uncommonly prescribed by doctors and there's a general lack of awareness. Still works vs BA.5 An excellent patient page @JAMA_current https://t.co/Exn82D8712 @AnuMalaniMD https://t.co/Rpdhcgg33h

Links:

Eric Topol EricTopol ( View Tweet)
Risk of hospitalized infection (SIE) goes up with #RA disease activity. Study of 3,254 RA Pts with 529 SIE - SIE rates lowest with remission (3.8/100PY), vs low dz activity (6.6/100PY; OR 1.60) vs moderate activity (8.8/100PY; OR 183) https://t.co/EWbX7N7fiG https://t.co/Y8bRn2XATF

Links:

Dr. John Cush RheumNow ( View Tweet)
New download available on the diagnosis & treatment of Still's Disease. Register on RheumNow and download for immediate use. https://t.co/YvgsEtVHVc https://t.co/N9K0cjfakC

Links:

Dr. John Cush RheumNow ( View Tweet)
Tonight! Sign up for Tuesday Night Rheumatology at 7pm! https://t.co/bnEXGUeeyx https://t.co/A4MaXWfhRO

Links:

Dr. John Cush RheumNow ( View Tweet)
Transcription factor ETS-related gene (ERG) is an orchestrator of lung capillary homeostasis & repair. Dysfunctional ERG signaling drives pulmonary vascular aging and persistent fibrosis https://t.co/TMFBa74ob7 https://t.co/n60DwGaa74

Links:

Dr. John Cush RheumNow ( View Tweet)
Heterozygous deficiency of Aggrecan (proteoglycan w/in cartilage) gene: manifests as inherited short stature, early-onset osteoarthritis, degenerative disc disease, osteochondritis dissecans, increasing joint pathology over time https://t.co/4iQdNL79oB https://t.co/qxStgE641v https://t.co/EHPJuIeQGt

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright 2024 All Rights Reserved.

×